ObsEva Added to the NASDAQ Biotechnology Index
GENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.
“We are proud to be included in the prestigious Nasdaq Biotechnology Index,” said Brian O’Callaghan, CEO of ObsEva. “Over the last year, we have made numerous achievements across all areas of the business, with significant progress against our clinical and regulatory milestones. Being part of this index enables us to reach new audiences and I look forward to this exciting next chapter as we continue to grow, bring innovation to the field of women’s health and build on our success to date."
The NBI is designed to track the performance of a set of securities listed on the Nasdaq Stock Market® (Nasdaq®), made up of Nasdaq-listed companies classified as Biotechnology & Pharmaceuticals by the Industry Classification Benchmark (ICB), and is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. The index is modified market capitalization-weighted such that constituents are capped at 8% (for the top five constituents) and at 4% (for the remaining constituents) at each quarterly index rebalance; the entire index is reviewed and reconstituted annually in December.
For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding ObsEva’s addition to the NASDAQ Biotechnology Index and the timing of such inclusion, and the clinical development of and commercialization plans for ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties; the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
+41 22 552 1550
+1 (617) 435-6602
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FutureDial Automation Solutions Process Over 231 Million Preowned Mobile Phones Worldwide25.1.2022 14:30:00 CET | Press release
Growing adoption of FutureDial’s robotics and automation software by Wireless Carriers, Third-Party Logistics Providers (3PLs) and Mobile Device Recyclers led to explosive volumes of preowned iPhones and Android Smartphones being processed for resale in 2021 SUNNYVALE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- FutureDial Incorporated continued its commanding lead in providing mobile device processing solutions for Wireless Carriers, Mobile Device Buy-Back & Trade-In Companies, Mobile Phone Recyclers and Third-Party Logistics Providers (3PLs) during the year, announcing that its robotics and automation software solutions have been used by customers in the mobile supply chain to data clear, functionally test and grade a cumulative total of over 231.4 Million pre-owned Android smartphones and iPhones worldwide, for resale on secondary markets. Additionally, the total number of functional tests using FutureDial software and robotics for quality assurance performed on preowned iPhones and A
HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder25.1.2022 14:30:00 CET | Press release
In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also established an office in the United States, furthering global expansion strategy MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for treating stress-axis related Major Depressive Disorder. These license agreements are part of a broader collaboration with the renowned Max-Planck-Society, comprising biomarker patent claims and therapeutic patent claims covering markets in Europe, the U.S., and now Asia, in particular Japan. Utilizing a more personalized approach to discovering new drugs in psychi
Mandalay Resources fortsätter att presentera utmärkta resultat från utvidgningsborrningen i Björkdalsgruvans östra del25.1.2022 14:25:01 CET | Pressemelding
Ådror med synligt guld och höga halter indikerar en uppgradering på djupet i Björkdal TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att meddela en uppdatering om utvidgningsborrningen i de östra delarna av Björkdalsverksamheten i Sverige. Nya borrningshöjdpunkter: Utvidgning av centrala området 47,7 g/t guld över 11,7 m (uppskattad sann bredd ”ETW” 5,85 m) i MU21-052: Inklusive 1 056,0 g/t över 0,40 m;47,5 g/t guld över 6,4 m (ETW 4,11 m) i MU21-047: Inklusive 716,0 g/t över 0,31 m; och507,0 g/t guld över 0,45 m (ETW 0,23 m) i MU21-051. Utvidgningstestning av centrala området 45,5 g/t guld över 2,3 m (ETW 1,15 m) i MU21-028;83,1 g/t guld över 0,4 m (ETW 0,39 m) i MU21-029;8,4 g/t guld över 5,7 m (ETW 5,35 m) in MU21-030; och5,1 g/t guld över 8,0 m (ETW 6,13 m) i MU21-031. Centralt område – Länk till Lake-området 13,2 g/t guld över 1,0 m (ETW 0,94 m) i MU21-028; och19,3 g/t guld över 0,4 m (ETW 0
Exterro Announces Significant Industry Promotion of its Document Review Platform25.1.2022 14:00:00 CET | Press release
Latest Version of Revamped Exterro Review Platform Optimized for Entire Legal Ecosystem; Limited-Time Only Promotion offers up to 6-Months Free Use of Platform PORTLAND, Ore., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Exterro Inc. – the preferred provider of Legal GRC software specifically designed for in-house legal, privacy, and IT teams at Global 2000 and AmLaw 200 organizations – today announced, for a limited-time only, a promotion of up to 6 free months and 5 terabytes of data storage of its Review platform. The promotion coincides with Exterro’s ongoing build out of its Review business unit and updated feature capabilities that are now available to the entire legal ecosystem, including legal service providers, law firms and corporate clients. Furthermore, the promotion of Clay Cocalis to Chief Revenue Officer and the addition of Don McLaughlin, Senior Vice President, Review Software represents the significant investment the company is placing in Exterro Review to ensure greater market s
Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration25.1.2022 14:00:00 CET | Press release
Marimekko Corporation, Stock Exchange Release, 25 January 2022 at 3.00 p.m. Shareholders’ proposals to the Annual General Meeting for the number of Marimekko’s Board members, the composition of the Board and its remuneration Shareholders representing in total approximately 27% of all of Marimekko Corporation’s shares and votes have made a proposal to the Annual General Meeting to be held on 12 April 2022 for the number of members of the Board of Directors, the composition of the Board and its remuneration. Proposal for the number of members of the Board of Directors Shareholders who represent approximately 27% of all of Marimekko Corporation’s shares and votes have informed the company that they propose to the Annual General Meeting that six (6) members be elected to the Board of Directors. Proposal for the composition of the Board of Directors The above-mentioned shareholders have also informed the company that they propose that Carol Chen, Mika Ihamuotila, Mikko-Heikki Inkeroinen and
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS25.1.2022 11:07:00 CET | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2022-01-25Loan2311Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,357 Volume bought, SEK mln500 Number of bids4 Number of accepted bids1 Average yield0.067 %Lowest accepted yield0.067 %Highest yield0.067 %% accepted at lowest yield 100.00 Auction date2022-01-25Loan2611Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,699 Volume bought, SEK mln500 Number of bids6 Number of accepted bids3 Average yield0.725 %Lowest accepted yield0.722 %Highest yield0.730 %% accepted at lowest yield 54.55 Auction date2022-01-25Loan2805Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,462 Volume bought, SEK mln500 Number of bids11 Number of accepted bids4 Average yield0.957 %Lowest accepted yield0.954 %Highest yield0.970 %% accepted at lowest yield 64.
RESULT OF RIKSBANK CERTIFICATE SALE25.1.2022 10:15:00 CET | Press release
AuctionAuction resultsAuction date2022-01-25Start date2022-01-26Maturity date2022-02-02Interest rate, %0.00Offered volume, SEK bn574.0Total bid amount, SEK bn2798.9Accepted volume, SEK bn574.0Number of bids16Percentage alloted, %20.508